StockData
CMPSNasdaqPharmaceutical PreparationsFiscal year ends December 31

COMPASS Pathways plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.11+0.36 (+3.35%)

Close on Oct 19, 2026

Market cap
$1.50B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 5, 2026Before market open–$-1.88–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026Before market open–$-0.30–
Q4 FY2025
Ended Dec 31, 2025
Mar 24, 2026Before market open–$-1.00–
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025Before market open–$-1.44–
Q2 FY2025
Ended Jun 30, 2025
Jul 31, 2025Before market open–$-0.41–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025Before market open–$-0.63–
Q3 FY2024
Ended Sep 30, 2024
Oct 31, 2024Before market open–$-0.56–
Q2 FY2024
Ended Jun 30, 2024
Aug 1, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 29, 2024Before market open–––

Company guidance

Outlook given with results on Nov 4, 2025, compared with the previous outlook

MeasurePeriodGuidancevs. prior
net cash used in operating activitiesFull year 2025$120.00M to $145.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements COMPASS Pathways filed with the SEC